Amgen ends Kyowa Kirin collaboration pending approval

Amgen Inc. filed an 8-K stating it signed a Termination Agreement with Kyowa Kirin Co., Ltd. to end their License and Collaboration Agreement dated June 1, 2021.

Rhea-AI Filing Summary

Amgen Inc. filed an 8-K stating it signed a Termination Agreement with Kyowa Kirin Co., Ltd. to end their License and Collaboration Agreement dated June 1, 2021. The termination will take effect once regulatory approval is received, meaning the prior collaboration will formally conclude only after that approval.

Insights

Biopharma corporate strategy analyst

Amgen and Kyowa Kirin agreed to end a material collaboration, pending regulatory approval.

Amgen and Kyowa Kirin have entered a Termination Agreement to end a License and Collaboration Agreement originally signed on June 1, 2021. The filing classifies this as a termination of a material definitive agreement, indicating the collaboration was significant to at least one party’s operations or pipeline.

The termination becomes effective only after regulatory approval, so there is a transition period where existing obligations may continue under the prior agreement. The exhibit includes redactions for information the company deems immaterial and confidential, which is typical for commercial terms in biopharma collaborations.

Subsequent disclosures may clarify how this change affects Amgen’s development plans or partnered assets associated with the June 2021 agreement, once regulatory approval is obtained and the termination is fully effective.

8-K Event Classification

2 items: 1.02, 9.01

2 items

Item 1.02 Termination of a Material Definitive Agreement Business

A significant contract was terminated, which may affect business operations or revenue.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did Amgen (AMGN) terminate with Kyowa Kirin?

Amgen terminated a License and Collaboration Agreement with Kyowa Kirin dated June 1, 2021. A new Termination Agreement dated January 30, 2026 sets the terms under which the original collaboration will be ended between the two companies.

When does the Amgen and Kyowa Kirin termination become effective?

The termination of the Amgen–Kyowa Kirin License and Collaboration Agreement becomes effective upon receipt of regulatory approval. Until that approval is received, the original June 1, 2021 agreement remains in place and continues to govern the relationship between the parties.

Why did Amgen file an 8-K about the Kyowa Kirin agreement?

Amgen filed an 8-K because the Kyowa Kirin License and Collaboration Agreement was considered a material definitive agreement. Terminating such an agreement triggers a disclosure requirement, so investors are formally informed that this significant collaboration will end after regulatory approval.

Where can investors find details of Amgen’s Termination Agreement with Kyowa Kirin?

Details are in Exhibit 10.1 to the 8-K, which is the Termination Agreement dated January 30, 2026. Some portions are omitted because Amgen considers them immaterial and confidential, a common practice for sensitive commercial terms.

Does the Amgen 8-K with Kyowa Kirin include financial results or earnings data?

No, this 8-K focuses on terminating a material definitive agreement with Kyowa Kirin. It describes the Termination Agreement and the effective date condition but does not provide financial results, revenue, or earnings figures for Amgen.

Who signed the Amgen 8-K related to the Kyowa Kirin termination?

The 8-K was signed on behalf of Amgen Inc. by Jonathan P. Graham, who serves as Executive Vice President and General Counsel and Secretary, reflecting his responsibility for corporate and legal affairs disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 08:00 AM Learn about SEC filing dates

AMGEN INC false 0000318154 0000318154 2026-01-30 2026-01-30 0000318154 us-gaap:CommonStockMember 2026-01-30 2026-01-30 0000318154 us-gaap:SeniorNotesMember 2026-01-30 2026-01-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 30, 2026

Amgen Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37702		95-3540776
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
One Amgen Center Drive
Thousand Oaks
California				91320-1799
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code

(805) 447-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		AMGN		The Nasdaq Stock Market LLC
2.000% Senior Notes due 2026		AMGN26		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.02 Termination of a Material Definitive Agreement.

On January 30, 2026, Amgen Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Kyowa Kirin Co., Ltd. (“Kyowa Kirin”), pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the “License and Collaboration Agreement”). The termination of the License and Collaboration Agreement will become effective upon receipt of regulatory approval.

The foregoing description of the Termination Agreement and the termination of the License and Collaboration Agreement does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, which is filed as Exhibit 10.1 hereof and which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

10.1		Termination Agreement, dated January 30, 2026, by and between Amgen Inc. and Kyowa Kirin Co., Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				AMGEN INC.
Date: January 30, 2026				By:		/s/ Jonathan P. Graham
				Name:		Jonathan P. Graham
				Title:		Executive Vice President and General Counsel and Secretary